



BAFNA PHARMACEUTICALS LTD.,

REGD. OFFICE: "BAFNA TOWERS" 299, THAMBU CHETTY STREET, CHENNAI-600 001, INDIA.
PHONE:+044-25267517/25270992, FAX:91-44-25231264, Email: info@bafnapharma.com, website: www.bafnapharma.com

27.07.2013

Ref: BPL/ 273 /2013-14

Listing Department
The Bombay Stock Exchange Limited
P J Towers
Dalal Street
Mumbai – 400 001
SCRIP CODE: 532989

Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E)
Mumbai – 400051
SCRIP SYMBOL: BAFNAPHARM

ISIN: INE878I01014

Dear Sir

Sub: Address to investors – continued selling of our stock

This is being addressed to all our valued investors and others concerned with the company with regard to continued selling of our stock during the past few days.

The company is doing well and we were able to achieve the targets for the financial year 2012-13 which is further evidenced by Boards approval for payment of dividend for the financial year 2012-13. We are focusing on increasing our orders along with existing orders. And there is no change in business fundamentals.

As on date, none of the shares pledged by the promoters were defaulted, as informed by the Promoters. And nothing adverse has happened during the recent past which will have impact on the performance of the company. We could not find any reason for this continued selling of our stock.

We assure our valued investors that, we are totally committed to the company for its development.

Thanking you

Yours faithfully

For BAFNA PHARMACEUTICALS LIMITED

Bafna Mahaveer Chand
Chairman & Managing Director

About Bafna Pharmaceuticals Ltd:

The company has 178 products registered in UK, Sri Lanka, Nepal, Ukraine, Ghana, Ethiopia, Philippines, Kryghistan, Georgia, Honduras, Colombia, Uzbekistan, Vietnam, Nigeria & Costa Rica. The company has two manufacturing facilities. A WHO-GMP certified manufacturing facility in Madhavaram, which is a 100 percent Export oriented Unit (EOU) and an EU GMP (UK MHRA), facility at Grantlyon, Chennai. Recently, the company received Australian TGA approval, Good Manufacturing Practices (GMP) approval from Ethiopia's Drug Administration and Control Authority (DACA) and also received approval from Ministry of Health and Social Welfare - Tanzania Food and Drugs Authority for its non-betalactam facility.

The company in the month of April 2010 inaugurated its Research and Development (Formulation) (FR&D) facility, a pilot plant in Chennai. The company has secured ISO 9001: 2008 Certificate of Registration for Manufacture and Export of Pharmaceutical products. Bafna Pharma has also received EU GMP Compliances from (MHRA) Medicines and Healthcare products Regulatory Agency, U.K. This accreditation has made Bafna Pharmaceuticals the 35th facility to achieve this key recognition in India and has opened the gates for exploring markets of European Union.

Bafna Pharma has recently acquired marquee brand "RARICAP" from Johnson & Johnson Associate Company.

Bafna Pharma has recently received Merit Award for the year 2012 from the State Pharmaceuticals Corporation of Sri Lanka during the 16th SPC Suppliers' Convention 2013.

Safe Harbour

This release contains "forward looking statement" within the meaning of applicable securities laws and regulations. Actual results could differ materially from those expressed or implied. Important factors that could influence the Company's performance include economic developments within & outside the country, demand and supply conditions in the industry, changes in input prices, changes in Government regulations, tax laws and other factors such as litigation and industrial relations. Bafna Pharma undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.